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vaccines are available to combat pneumonia, however, in 














































Prior to 2005, the expensive cost of the Hib conjugate 
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conjugate vaccine has been available for more tha 10 years 









































and pneumococcal conjugate vaccines and their global 
impact on the disease burden of childhood pneumonia. 
It also provides an overview of the development of new 




        pneumonia in children
2.1.  Hib conjugate vaccines

























vaccines are composed of capsular polysaccharide, 

































































































































monovalent Hib conjugate vaccine can be administered 
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2.2.  Pneumococcal vaccines
The four pneumococcal vaccines commercially available, 












































































































other geographic regions of the world due to serotypes not 












































of non-typeable	(NTHi), Protein D, as the main 




































































of the two new pneumococcal conjugate vaccines was 























































































































































































































































































of pneumococcal conjugate vaccines on pneumonia 
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age groups.  There was also evidence of increases in non-











caused by all serotypes had declined in children younger 
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The widespread use of PPV-23 has been restricted 
















































































































































analysis of the immunogenicity of pneumococcal 


















































invasive disease was evaluated in children from the 












































































































































immunological hyporesponsiveness was observed by 
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pneumonia disease burden, Australian Indigenous children 







































followed by a PPV-23 booster in the second year of 


















the incidence of invasive pneumococcal disease in 


































































































































































































the Northern Territory.  A booster dose of PCV-13 was 
recommended at 12-18 months of age for Indigenous 
children in areas of high incidence, replacing the PPV-23 
booster.
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PRP-OMP was replaced with PRP-TT.  Of concern, is the 







































(NCT01215188) study on a 15-valent pneumococcal 
































































serotypes.  Whilst this early clinical data looks promising 











to limited serotype coverage, serotype replacement and 






























































































expressed by all pneumococci, to be immunogenic.  Sera 









































































has yet to be shown in humans.  In light of the propensity 












to gain greater potency, there has been an emphasis to 
develop candidate vaccines with more than one common 
protein.
The most advanced protein-based pneumococcal vaccine 




























S. pneumoniae, including 











































































































PHiD-CV) were compared with PHiD-CV and found to be 
well tolerated and immunogenic in Czech toddlers when 











is currently being trialled for safety, immunogenicity 
and impact on nasopharyngeal carriage in The Gambia 






















D. Otczyk et al / pneumonia 2013 Feb 14;2:2-15




























































designed to assess the safety and immunogencity of the 
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PhtD, PcpA, PlyD1, 
PcpA/PhtD
































dPly, PhtD/dPly,    
dPly/PHiD-CV,  
PhtD/dPly/PHiD-CV




























Whole cell Killed, non-
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candidates, PcpA and PcpA/PhtD, were found to be safe 













































































































































































































































































































































































































enterica serovar Typhimurium vector expressing 

















































enterica serovar Typhimurium strain expressing PspA 
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assessments on the impact of pneumococcal conjugate 






































































or superiority to the currently available polysaccharide 













































































































































































































































































































































































































































































































































(TPP) for the Advance Market Commitment (AMC) 
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pneumococcal conjugate vaccine in children. Northern 




























vaccine against pneumonia and invasive pneumococcal 
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23-valent pneumococcal polysaccharide vaccine at 12 








































pneumococcal conjugate vaccine, and is enhanced by 






































dose following pneumococcal polysaccharide vaccine at 12 
















































































































































































































































































































































































































































































et al. The changing epidemiology of invasive pneumococcal 
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childcare centers in the Northern Territory, Australia, 
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of Streptococcus pneumoniae mediates adherence 
































































































et al. Safety and immunogenicity of pneumococcal protein 














































































































































































































pneumoniae in humans: comparisons between adults and 





























































et al. Immune responses to recombinant pneumococcal PsaA 
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